Subtype
Lung Neuroendocrine Carcinoma
CI-CAN-00003107Explore in graph →
389 active trials6 approved drugs6 evidence items
- NCIt
- C45569
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003107Explore in graph →
Clinical trials
1,113 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (159)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01574300 | Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network(CASTLE) | terminated | — | 136 | Addario Lung Cancer Medical InstituteOTHER | 0 | Jan 10, 2020 | clinicaltrials |
| NCT04192682 | Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 40 | Changzhou Cancer Hospital of Soochow UniversityOTHER | 1 | Jan 6, 2020 |
| clinicaltrials |
| NCT01165658 | Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies | terminated | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01880528 | Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer | completed | Phase 2 | 23 | Mayo ClinicOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT03811652 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | completed | Phase 1 | 8 | MedImmune LLCINDUSTRY | 2 | Dec 30, 2019 | clinicaltrials |
| NCT04213937 | Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 386 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | completed | Phase 1 | 128 | AbbVieINDUSTRY | 1 | Nov 29, 2019 | clinicaltrials |
| NCT03700359 | A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC | unknown | Phase 2 | 60 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT04171986 | Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis | unknown | N/A | 93 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00388960 | Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 99 | CelgeneINDUSTRY | 5 | Nov 19, 2019 | clinicaltrials |
| NCT04168281 | Watchful Observation of Patients With LD-SCLC Instead of the PCI(PCILESS) | unknown | N/A | 80 | Sergiusz NawrockiOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT01999881 | Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients | completed | N/A | 21 | University of Wisconsin, MadisonOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT00617409 | To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid | completed | Phase 2 | 69 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT02511795 | AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | completed | Phase 1 | 128 | AstraZenecaINDUSTRY | 2 | Nov 7, 2019 | clinicaltrials |
| NCT00547651 | AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy | completed | Phase 3 | 637 | CelgeneINDUSTRY | 17 | Nov 6, 2019 | clinicaltrials |
| NCT00375193 | Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy | completed | Phase 2 | 75 | CelgeneINDUSTRY | 3 | Oct 24, 2019 | clinicaltrials |
| NCT02030184 | Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas | withdrawn | Phase 1 / Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT04128800 | Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT00923884 | Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer | completed | — | 546 | National Cancer Institute (NCI)NIH | 1 | Oct 9, 2019 | clinicaltrials |
| NCT00483509 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma(NGR007) | completed | Phase 2 | 28 | AGC Biologics S.p.A.INDUSTRY | 1 | Oct 4, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT01025284 | A Study for Participants With Small-Cell Lung Cancer | completed | Phase 2 | 64 | Eli Lilly and CompanyINDUSTRY | 3 | Sep 17, 2019 | clinicaltrials |
| NCT02937402 | Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer | terminated | N/A | 9 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT03503890 | Expanded Access to Rovalpituzumab Tesirine | no longer available | — | — | AbbVieINDUSTRY | 0 | Sep 10, 2019 | clinicaltrials |
| NCT04073550 | Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer | unknown | Phase 3 | 184 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 29, 2019 | clinicaltrials |
| NCT03994744 | Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | unknown | Phase 2 | 68 | Hunan Cancer HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT04056949 | Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy | unknown | Phase 2 | 30 | Junling LiOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02949895 | Study of BMS-986012 in Subjects With Small Cell Lung Caner | completed | Phase 1 | 7 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 12, 2019 | clinicaltrials |
| NCT02109016 | A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations | terminated | Phase 2 | 18 | Clovis Oncology, Inc.INDUSTRY | 5 | Jul 29, 2019 | clinicaltrials |
| NCT01439568 | A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | terminated | Phase 1 | 9 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jun 26, 2019 | clinicaltrials |
| NCT03971214 | PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer(PICARES) | unknown | Phase 1 | 6 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT01040312 | An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors | completed | — | 321 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | May 23, 2019 | clinicaltrials |
| NCT02069158 | Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor(IOSI-NDU-001) | completed | Phase 1 | 17 | Cristiana SessaOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT03059797 | Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) | completed | Phase 2 | 120 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 16, 2019 | clinicaltrials |
| NCT01253369 | Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT01173523 | Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 25 | David M. Jackman, MDOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01317953 | Oral Green Tea Extract for Small Cell Lung Cancer | available | — | — | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT02605811 | Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer | unknown | Phase 2 | 426 | Guangzhou Medical UniversityOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT03841136 | Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT03890055 | Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride | unknown | Phase 4 | 30 | Chifeng Municipal HospitalOTHER | 0 | Mar 26, 2019 | clinicaltrials |
| NCT02542137 | Abscopal Effect for Metastatic Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 0 | Mar 21, 2019 | clinicaltrials |
| NCT01069653 | Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer | completed | Phase 1 | 9 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03871205 | Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer | unknown | Phase 1 | 30 | Shenzhen People's HospitalOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT03077854 | Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial | unknown | N/A | 64 | National Taiwan University HospitalOTHER | 1 | Mar 11, 2019 | clinicaltrials |
| NCT00969306 | Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients(Chloroquine IV) | terminated | Phase 1 | 5 | Maastricht Radiation OncologyOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03239171 | Bioinformation Therapy for Lung Cancer | completed | Phase 2 / Phase 3 | 120 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT03162705 | Molecular Profiling in Small Cell Lung Cancer(MPSCLC) | unknown | — | 120 | Zhujiang HospitalOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT01286987 | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 113 | PfizerINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT01722292 | A Study of LY2940680 in Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 26 | Eli Lilly and CompanyINDUSTRY | 2 | Dec 28, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jan 10, 2020source: clinicaltrials